TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31484277

Group type: EXPERIMENTAL
Intervention: Indocyanine green near-infrared fluorescence imaging for extrahepatic cholangiography
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional X-ray cholangiopancreatography
Number of subjects: 48
Study: 28430684

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (1.5 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 200
Study: 25922454

Group type: EXPERIMENTAL
Intervention: Hip resurfacing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cementless total hip arthroplasty
Number of subjects: 80
Study: 23905378

Group type: EXPERIMENTAL
Intervention: Bushen quhan zhiwang decoction (BQZD) combined with methotrexate (MTX) 10 mg/week
Number of subjects: 240

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 10 mg/week alone
Number of subjects: 240
Study: 21448208

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (cord clamped at 35.2±10.1 s)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Immediate cord clamping (cord clamped at 7.9±5.2 s)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (DCC and immediate cord clamping)
Number of subjects: 33
Study: 19304088

Group type: EXPERIMENTAL
Intervention: AcrySof MA60AC (Group 1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT (Group 2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: AcrySof SN60AT (Group 3)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 59
Study: 16979636

Group type: EXPERIMENTAL
Intervention: FOXO3A mutations (2/90; 2.2%)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FOXO1A mutations (1/90; 1.1%)
Number of subjects: 90
Study: 15570766

Group type: EXPERIMENTAL
Intervention: On-pump conventional coronary artery surgery (150 patients)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Off-pump surgery (150 patients)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB) inclusive of cardioplegic arrest
Number of subjects: 300
Study: 10855632

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (once-daily, subcutaneous)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard, continuous, adjusted-dose intravenous heparin
Number of subjects: 157
Study: 9115057

Group type: EXPERIMENTAL
Intervention: Intravenous fenoldopam (titrated up to 0.5 microgram/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous fenoldopam
Number of subjects: 0
Study: 8327167

Group type: EXPERIMENTAL
Intervention: Forane (inhalation anesthetic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol (intravenous anesthetic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forane (inhalation anesthetic) at higher concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous anesthetic
Number of subjects: 0
Study: 3544181

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 29858411

Group type: EXPERIMENTAL
Intervention: m-Health SMS reminders for ADA guidelines for 5 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: m-Health SMS reminders for ADA guidelines
Number of subjects: 62
Study: 27488081

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg twice per day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 24237751

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 10% solution once daily for 2 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Hydroquinone 4% solution once daily for 2 months
Number of subjects: 93
Study: 22373561

Group type: EXPERIMENTAL
Intervention: Automatic image realignment mechanism activated mid-task
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endoscopic image perfectly aligned with the actual task space (0° image orientation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endoscopic image misaligned (various degrees of deviation from 0°)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Various image orientations (8 total)
Number of subjects: 24
Study: 22750263

Group type: EXPERIMENTAL
Intervention: Topical clonazepam
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 18597830

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg once daily titrated to 100 mg once daily)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 16093466

Group type: EXPERIMENTAL
Intervention: Early insertion of tympanostomy tubes
Number of subjects: 429

Group type: COMPARATOR
Intervention: Delayed insertion of tympanostomy tubes
Number of subjects: 429
Study: 11929471

Group type: EXPERIMENTAL
Intervention: Radical nephrectomy via a transperitoneal approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extraperitoneal (translumbar) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery for non-disseminated disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic therapy and combined treatments
Number of subjects: 0
Study: 12073205

Group type: EXPERIMENTAL
Intervention: CPB initiated at F(I)O(2) of 1.0 (Group II, n = 7)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CPB initiated at F(I)O(2) of 0.21 (Group III, n = 7)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CPB initiated at F(I)O(2) of 1.0 (Group I, n = 10)
Number of subjects: 24
Study: 9673439

Group type: EXPERIMENTAL
Intervention: 30 mg oral D‐fenfluramine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: D‐fenfluramine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: DL‐fenfluramine
Number of subjects: 7
Study: 8020648

Group type: EXPERIMENTAL
Intervention: Reinforcer duration of 0.5 sec
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reinforcer duration of 1.5 sec
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reinforcer duration of 4.0 sec
Number of subjects: 60
Study: 2500718

Group type: EXPERIMENTAL
Intervention: Oral enoxacin 400 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intramuscular ceftriaxone 250 mg
Number of subjects: 57
Study: 31373430

Group type: EXPERIMENTAL
Intervention: Lateral approach injection of 40 mg/ml triamcinolone acetonide (Kenalog) and 4 ml 1% lignocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Posterior approach injection of 40 mg/ml triamcinolone acetonide (Kenalog) and 4 ml 1% lignocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study: 28701593

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2 μg/kg/min following anesthesia induction till the end of the surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo (no intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no renal dysfunction)
Number of subjects: 60
Study: 25716463

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 4832

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4832
Study: 22974973

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 1200 mg catechins, 240 mg caffeine/day for 7 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 27
Study: 21375794

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg) + Hydrocortisone (30 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 19454560

Group type: EXPERIMENTAL
Intervention: Group 65 (mean perfusion pressure 60‐69.9 mmHg, n=68)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Group 55 (mean perfusion pressure lower than 60 mmHg, n=59)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Group 75 (mean perfusion pressure 70 mmHg and higher, n=52)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Group with ARF (n=19)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Group without ARF (n=160)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Age, valve replacement/reconstruction surgery, combined valve and CABG surgery, duration of CPB, duration of aortic cross‐clamp
Number of subjects: 179
Study: 16998292

Group type: EXPERIMENTAL
Intervention: PIVKA-II
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: PIVKA-II + AFP
Number of subjects: 227
Study: 12664221

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Proportional Assist Ventilation (PAV) 80
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV) 50
Number of subjects: 20
Study: 11149433

Group type: EXPERIMENTAL
Intervention: Desflurane (n = 20)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 22)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Propofol (n = 10)
Number of subjects: 52
Study: 9194006

Group type: EXPERIMENTAL
Intervention: Relaxation before the scan
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Relaxation before and during the scan
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 139
Study: 1288905

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG)
Number of subjects: 20
Study: 31927671

Group type: EXPERIMENTAL
Intervention: Balanced Korean Diet (BKD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Typical American Diet (TAD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 2010 Dietary Guidelines for Americans (2010DGA)
Number of subjects: 61
Study: 28056704

Group type: EXPERIMENTAL
Intervention: OPFAϖ‐3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26669965

Group type: EXPERIMENTAL
Intervention: Dianatal obstetric gel
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (labor management without obstetric gel)
Number of subjects: 200
Study: 24412138

Group type: EXPERIMENTAL
Intervention: Heart rate characteristics index displayed to clinicians
Number of subjects: 274

Group type: COMPARATOR
Intervention: Conventional monitoring (heart rate characteristics index not displayed to clinicians)
Number of subjects: 274
Study: 22558691

Group type: EXPERIMENTAL
Intervention: lavender oil
Number of subjects: 115

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 115
Study: 20233524

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome prevalence
Number of subjects: 3785

Group type: EXPERIMENTAL
Intervention: Risk factors for metabolic syndrome
Number of subjects: 3785
Study: 17932127

Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g stat.
Number of subjects: 212

Group type: COMPARATOR
Intervention: Doxycycline for 9 days
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Extended azithromycin (500 mg on day 1 followed by 250 mg daily for 4 days)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Extended doxycycline treatment
Number of subjects: 212
Study: 15965438

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 11802751

Group type: EXPERIMENTAL
Intervention: Gemfibrozil therapy
Number of subjects: 0
Study: 10717778

Group type: EXPERIMENTAL
Intervention: EE/GSD
Number of subjects: 1476

Group type: COMPARATOR
Intervention: EE/DSG
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 1476
Study: 7741777

Group type: EXPERIMENTAL
Intervention: Slow-release propafenone 2 x 225 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slow-release propafenone 2 x 325 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slow-release propafenone 2 x 425 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All doses of slow-release propafenone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R-form of propafenone
Number of subjects: 24
Study: 1784666

Group type: EXPERIMENTAL
Intervention: Humorous treatment (humor condition)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nonhumorous condition (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Humorous stimuli
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nonhumorous stimuli
Number of subjects: 31
Study: 6294794

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 656
Study: 30998059

Group type: EXPERIMENTAL
Intervention: Online expressive writing intervention
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 508
Study: 29846832

Group type: EXPERIMENTAL
Intervention: Helium-neon laser therapy (HNLT) and conventional therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Infrared laser therapy (ILT) and conventional therapy
Number of subjects: 65
Study: 26824517

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE) with 0.5 kg dumbbell, performed twice a day for 8 weeks after complex decongestive physiotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-progressive resistance exercise (non-PRE) group
Number of subjects: 32
Study: 24916467

Group type: EXPERIMENTAL
Intervention: EVLTAP (endovenous laser therapy with ambulatory phlebectomy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: EVLA alone with sequential phlebectomy
Number of subjects: 50
Study: 22402727

Group type: EXPERIMENTAL
Intervention: Direct application of vibratory stimuli
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stretch group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rest group
Number of subjects: 36
Study: 19327167

Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 158
Study: 17767943

Group type: EXPERIMENTAL
Intervention: Predictable condition (color change at a fixed time)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-change condition (color does not change)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpredictable condition (color change at random times)
Number of subjects: 0
Study: 15143446

Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 11262534

Group type: EXPERIMENTAL
Intervention: Two-dimensional echocardiography (2-D echo) using apical four-chamber (4C) and two-chamber (2C) views
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Area-length 2-D echo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Eyeball cineangiography
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Eyeball 2-D echo (method of discs)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Eyeball 2-D echo (area-length)
Number of subjects: 63
Study: 9704764

Group type: EXPERIMENTAL
Intervention: Newly developed health-related quality-of-life measure
Number of subjects: 137
Study: 7986236

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract LI 1370 (Kaveri forte) 150 mg daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract LI 1370 (Kaveri forte)
Number of subjects: 11
Study: 2919733

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg every 6 hours for 72 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No ranitidine (control group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No ranitidine (nonoperative control group)
Number of subjects: 40
Study: 31243685

Group type: EXPERIMENTAL
Intervention: 200 μg chromium
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 30335211

Group type: EXPERIMENTAL
Intervention: CBT‐ACT intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 28
Study: 28213592

Group type: EXPERIMENTAL
Intervention: 8 weeks of supervised exercise training
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study: 25789270

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 2% (10 ml every 3 hours, six times a day for 6 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Magic mouthwash (10 ml every 3 hours, six times a day for 6 days)
Number of subjects: 30
Study: 24165976

Group type: EXPERIMENTAL
Intervention: Fedratinib (10-680 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22023525

Group type: EXPERIMENTAL
Intervention: ATG 4.5 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: ATG 7.5 mg/kg
Number of subjects: 20
Study: 19954486

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 117
Study: 17299112

Group type: EXPERIMENTAL
Intervention: 800 IU/d natural vitamin E for 3 months, increased to 1200 IU/d for a further 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15631129

Group type: EXPERIMENTAL
Intervention: Visualization methods that showed the sign of vectors within the vector field
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visualization methods that visually represented integral curves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visualization methods that visually represented the locations of critical points
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expert user performance
Number of subjects: 0
Study: 12081335

Group type: EXPERIMENTAL
Intervention: Medizip Surgical Zipper technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional (needle and thread) control group
Number of subjects: 50
Study: 9607385

Group type: EXPERIMENTAL
Intervention: Irbesartan 50 mg
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Irbesartan 100 mg
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Irbesartan 200 mg
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Irbesartan (all doses > or = 50 mg)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg added to irbesartan
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study: 7617573

Group type: EXPERIMENTAL
Intervention: Training with individual feedback
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Training without feedback
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 1369847

Group type: EXPERIMENTAL
Intervention: Trochanteric osteotomy performed in 79 hips (11%) of 68 patients
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Trochanter reattached by Charnley, Coventry or Amstutz method in 73 hips
Number of subjects: 594
Study: 352788

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg per day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 55
Study: 30993836

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 low-dose prophylaxis (20-30 IU/kg twice-weekly)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 high-dose prophylaxis (30-40 IU/kg 3 times weekly)
Number of subjects: 23

Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 prophylaxis
Number of subjects: 23
Study: 28255768

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 mcg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 mcg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mcg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 120
Study: 25930038

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study: 24081373

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 60
Study: 21529210

Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 19095991

Group type: EXPERIMENTAL
Intervention: ON antithrombotics
Number of subjects: 568

Group type: COMPARATOR
Intervention: OFF antithrombotics
Number of subjects: 568
Study: 17065971

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15513569

Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study: 10420862

Group type: EXPERIMENTAL
Intervention: 3-hour case-based educational session on clinical practice guidelines (CPGs) for depression and access to a psychiatrist for consultation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Receipt of CPGs without educational session or access to the psychiatrist
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Consultation with psychiatrist
Number of subjects: 42

Group type: COMPARATOR
Intervention: No consultation with psychiatrist
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Physicians' ratings of depression severity before treatment and at 6 months
Number of subjects: 42
Study: 7579485

Group type: EXPERIMENTAL
Intervention: rh GM-CSF (5 micrograms/kg/d for at least ten days)
Number of subjects: 11
Study: 2317420

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine 4 ml at the L2‐3 spinal interspace (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine 4 ml at the L4‐5 spinal interspace (n = 20)
Number of subjects: 40
Study: 7441484

Group type: EXPERIMENTAL
Intervention: Superimposed presentation of images
Number of subjects: 43

Group type: COMPARATOR
Intervention: Separated presentation of images
Number of subjects: 43
Study: 30289872

Group type: EXPERIMENTAL
Intervention: High Frequency (HF) resistance training (5 times per week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low Frequency (LF) resistance training (2 or 3 times per week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High Frequency (HF) resistance training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low Frequency (LF) resistance training
Number of subjects: 20